Advances in treating metastatic breast cancer. Don't miss this opportunity to engage with ex...
Advances in treating metastatic breast cancer. Don't miss this opportunity to engage with experts, ask questions in real time, and access downloadable reference slides to support decision-making for patients with endocrine-resistant, ESR1-mutated metastatic breast cancer. 5 days ago · The study randomized people with ER-positive, HER2-negative, locally advanced or metastatic breast cancer to receive giredestrant or the aromatase inhibitor letrozole in combination with Pfizer 5 days ago · Giredestrant plus palbociclib did not yield a statistically significant PFS improvement in ER-positive/HER2-negative locally advanced or metastatic breast cancer. The study did not meet its 5 days ago · AstraZeneca and Daiichi Sankyo’s supplemental Biologics License Application (sBLA) for Enhertu (trastuzumab deruxtecan) has been accepted and granted Priority Review in the US for the treatment of adult patients with HER2-positive breast cancer who have residual invasive disease after neoadjuvant HER2-targeted treatment. 5 days ago · Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today results from the Phase III persevERA Breast Cancer study evaluating investigational giredestrant in combination with palbociclib for people with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer. Thanks to research, more patients are living with MBC than ever before—but it remains incurable. The radiopharmaceutical was developed by RayzeBio Inc. Oct 18, 2025 · Patients with estrogen-receptor positive HER2 negative advanced breast cancer showed significantly improved progression-free survival when treated with an oral combination regimen that includes giredestrant, a novel, next-generation selective estrogen receptor degrader and full antagonist, compared to a standard combination approach. May 20, 2024 · Stage 3 breast cancer means that the breast cancer has extended to, or spread, beyond the immediate region of the cancerous tumor and may have invaded nearby lymph nodes and muscles, but it has not spread to distant organs, such as the bones, liver, lungs, or brain. , the sponsor of the active phase 1b/2 clinical trial. Jun 19, 2025 · Investigators presented several potentially practice-changing treatment advances for these patients At the annual meeting of the American Society of Clinical Oncology (ASCO), there was a keen focus on metastatic breast cancer (MBC). In the early-stage setting, up to a third of people eventually experience disease recurrence on or after adjuvant endocrine therapy treatment. The Food and Drug Administration (FDA) grants Priority Review to 2 days ago · How Does BRCA Mutation Status Impact Outcomes in Young Luminal Breast Cancer Patients? —A recent propensity-matched cohort study found BRCA mutation carriers exhibited more aggressive tumor Don't miss this opportunity to engage with experts, ask questions in real time, and access downloadable reference slides to support decision-making for patients with endocrine-resistant, ESR1-mutated metastatic breast cancer. 1,2 1 day ago · In preclinical studies, data indicate that actinium-225 DOTATATE demonstrated feasibility and potential efficacy for the treatment of ER+ metastatic breast cancer in the laboratory by targeting somatostatin receptor subtype 2 expression. Mar 25, 2025 · Further Reading: Recent Advances with Precision Medicine Treatment for Breast Cancer including Triple-Negative Sub-Type Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival Is a Cure Possible for Breast Cancer Metastatic to the Liver? 5 days ago · New data push ADCs earlier, reshaping HER2+ metastatic breast cancer sequencing, maintenance, and trial strategy. The goal of these interventions shifts from eradication to controlling disease progression and alleviating symptoms. These findings, from the phase 3 evERA Breast Cancer study Mar 29, 2024 · Metastatic breast cancer, or stage 4 breast cancer, means cancer has spread to other organs and may result in new symptoms. Genome-driven precision oncology has led to the approval of targeted therapies based on specific molecular alterations, with some approvals specific to breast cancer and others being tumor-agnostic. Bone metastasis commonly causes persistent pain in the affected area, bones that fracture more easily than normal, and elevated calcium levels in the blood. Aug 12, 2025 · The following European Society for Medical Oncology (ESMO) Living Guideline has been recently updated with new treatment recommendations: ESMO Metastatic Breast Cancer (MBC) Living Guideline. Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease (FourLight-3) 5 days ago · Despite treatment advances, ER-positive breast cancer remains particularly challenging to treat due to its biological complexity. There’s no cure, but with treatment, survival rates continue to 3 days ago · A breast cancer that has spread to bone is still breast cancer, but the symptoms it causes are bone symptoms. Investigators are expanding our understanding of MBC and These findings strongly support the notion that genomic/molecular alterations must guide treatment decisions to optimize patient outcomes. . 6 days ago · Phase 3 study of RLY-2608 + fulvestrant vs capivasertib + fulvestrant as treatment for locally advanced or metastatic PIK3CA-mutant HR+/ HER2- breast cancer (ReDiscover-2). Although this stage is considered to be advanced, there are a growing number of effective treatment options for Stage 3 breast ESMO Treatment Guidelines for Advanced Stages Systemic treatment for breast ca metastasis usually involves a combination of chemotherapy, endocrine therapy, and biological agents. fzkosmeb vqnjo ottqwa uwm ekqczsb qabic dnqe nbsbf gloszjh dywaf
